Global BioPharma Market Outlook 2014: Rising Stars & Mature Companies Analysis in New Research Reports at

Share Article

Global Pharmaceutical and Biotechnology Outlook 2014 reports provide analysis of small research focused companies in coming years, mature biotech companies next five years distinction and also analyzes biopharma/biotech companies in Japan and India.

Past News Releases


The report “Global Pharmaceutical and Biotechnology Outlook 2014: Rising Stars” says innovations have contributed to the availability of a range of new treatments for diseases resulting in improvement in the length and quality of life and reduced disease burden for individuals and society. However, the need for innovative therapies for unmet needs/challenging diseases continues to grow, accelerating the pace of drug development directly or through partnership/ in-licensing. We expect innovation and improved drug therapies through novel target discovery and technology platforms to continue to flow from the backyards of small research focused companies (Rising Stars, RS – non-profitable biotech companies) in coming years.

Complete details on the report at

Approval of new drugs, successful launches, maturing pipeline sustained the growth trajectory of biotech companies resulting in successful IPOs. We expect the optimism to percolate further into companies with novel technology platforms and targets. For more details on the trend in drug approvals, upcoming milestones and M&A in coming years please see Global Pharmaceutical and Biotechnology Outlook 2014: Rising Stars.

Purchase a copy of Report directly at

Global Pharmaceutical & Biotechnology Outlook 2014: Mature Biotech
Positive sentiments for the biotech sector have prevailed in the last two to three years, and we expect this trend to continue for the next year too. Our optimism is based on the continuity in the flow of innovative products from their pipeline, implementation of strategic decisions to improve cost efficiency, strengthen therapeutic leadership, and hedge against generic threats – which all lend stability to the business model of the company.

In the next five years the distinction between some mature biotech companies and large global pharma may become blurred esp. if there is consolidation within the sector.

The detailed 72 pages report contains the detailed discussion of the key attributes of leading biotech companies’ Acorda, Alexion, Amgen, Biogen Idec, Celgene, Gilead, Regeneron and Vertex.

Purchase a copy of report directly at

Global Pharmaceutical and Biotechnology Outlook 2014 - Japan Pharma: 2014 will be marked as a transition year for the Japanese Pharma industry - the year is bound to be painful both for innovators and generic companies due to the new regulations. We find these regulations to be 'decisive' in spurring generic penetration significantly, with the main beneficiary being the Japanese government (or society) and not the generic companies. The implications of new price-reversions are going to have many facets and will change conventional business models. We expect many support services industries - CMOs, CROs and other allied services industries to benefit from these structural changes, while API importers will suffer. We also expect consolidation and M&A activities to spur in Japan.

The 138 pages report contains the detailed discussion of Japan biopharmaceutical market – which includes- our view on the impact of 2014 price cuts on generic companies and innovator companies and detailed discussion on key attributes (consolidation activities, potential of R & D pipeline candidates, generic threat in the domestic Japan market etc.) of leading Japanese innovator companies:
1.    Astellas
2.    Chugai
3.    Daiichi Sankyo
4.    Dainippon Sumitomo
5.    Eisai
6.    Kyorin
7.    Kyowa hakko Kirin
8.    Mitsubishi Tanabe
9.    Shionogi
10.    Takeda
11.    and leading Japanese generic companies- Nippon Chemiphar, Sawai and Towa.

Purchase a copy of report directly at

Global Pharmaceutical and Biotechnology Outlook 2014 - India Pharma: Our outlook 2014 on India Pharma covers overall business and market growth for Indian companies, ParaIV filing, NCE pipeline and biosimilar and NDDS evelopment.

Key Topics Covered
1. Uniform Code on Sales and Marketing Practices in India
2. Issuance of warning letters to Indian facilities by USFDA: not a concern
3. Biosimilar perspective for Indian market
4. New drug discovery development in India
5. Biocon: Sits comfortable with its near and long term contributory products
6. Cadila Healthcare: NCE, Transdermal, Biosimilars and Complex generics launches thru 2016 –Eventful time ahead
7. Cipla: Major change in business model
8. Dr. Reddy’s Lab: Focus on Complex formulations and Biogenerics to intensify
9. Glenmark: US business, NCE and ParaIV will show significant growth
10. IPCA: Fine chemicals to formulation –Global leadership in select products
11. Lupin: US and Japan Business –Key for long term growth
12. Natco: Leveraging chemistry, formulation and IP strength –For Us and India Markets
13. Panacea Biotec: Financial trouble mounting, Acceptance of WHO prequalification and formulation business will revive the company
14. Shasun: On path to become fully integrated Pharma company
15. Shilpa Medicare: A leader in Oncology API, Expanding into Non-Onco, peptides and complex formulations
16. Sun Pharma: Strong Management Team - Absolute and Comparative Advantage

Purchase a copy of Report directly at

About Us: is an online market research reports library of 400,000+ in-depth studies of over 5000 micro markets. Call +1 888 391 5441 with your industry research requirements or email the details on sales(at)reportsandreports(dot)com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Priyank Tiwari
since: 06/2010
Follow >
Like >
Follow us on
Visit website